(Image: AI-predicted cell detection results of Biomy’s DeepPathFinder™. From the January 10, 2025 NEC press release.)
When I interact with the worldwide company NEC, I am usually dealing with automated biometric identification systems (ABIS).
Of course, ABIS is only a small part of what NEC does. It’s also involved in healthcare.
Consider…artificial intelligence and deep learning-powered digital pathology (“a field involving the digitization and computational analysis of pathology slides”).
“NEC Corporation (NEC; TSE: 6701) and Biomy, Inc. (Biomy) have signed a Memorandum of Understanding (MoU) for a joint marketing partnership to develop and expand artificial intelligence/deep learning (AI/DL)-based analytical platforms in the field of digital pathology. Through this partnership, the two companies aim to promote precision medicine for cancer patients and contribute to the advancement of the healthcare industry.”
So what is Biomy contributing?
“Biomy, which aims to realize personalized medicine through pathological AI technology, has developed DeepPathFinder™, a proprietary, cloud-based, AI/DL automated digital pathology analytical platform.”
And NEC?
“NEC has positioned healthcare and life sciences as a core pillar of its growth strategy. With a strong foundation in image analysis and other AI technologies, NEC has a long history of providing medical information systems such as electronic medical records to healthcare institutions.”
As I’ve said before, healthcare must deal with privacy concerns (protected health information, or PHI) similar to those NEC addresses in its other biometric product line (personally identifiable information, or PII). I personally can’t do nefarious things if I fraudulently acquire your digital pathology slide, but some bad actors could. Presumably the Biomy product is well protected.
Bredemarket 